GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) and GIP/GLP-1 dual agonists (tirzepatide) anchor the class, with a trial record that includes STEP (semaglutide for weight management, The New England Journal of Medicine , 2021), SURMOUNT (tirzepatide for weight management, NEJM 2022), and SURMOUNT-OSA (tirzepatide for obstructive sleep apnea, NEJM 2024)
- , ,
Pintaudi, B., Di Vieste, G
Medical Reasons to Take a Planned Break from Semaglutide Legitimate reasons for a temporary pause include severe nausea unresponsive to dose adjustment, planned surgery requiring medication pauses, acute illness, or pregnancy planning (as semaglutide safety in pregnancy is not established)
In 2017, Murata and collaborators reported that serum carnitine level was negatively correlated with severity of constipation in 27 patients